LONG MINI FUTURE - NOVO-NORDISK B | Real-time Bid/Ask 03:27:22 2024-05-31 am EDT | ||
| 0.84 CHF / 0.85 CHF | -1.74% |
|
| 3 months | +30.30% | ||
| 6 months | +160.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.86 | +3.61% |
Delayed Quote Swiss Exchange
Last update May 23, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| MNOBLV | |
| ISIN | CH1290585509 |
| Date issued | 2023-08-31 |
| Strike | 598.5 kr |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.21 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.86 CHF |
|---|---|
| Lowest since issue | 0.14 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.18% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
916.9
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.04%
- Stock Market
- Certificates
- MNOBLV Certificat
